Study guide

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women

Key Takeaways Explain This Topic AI

Diabetes mellitus is diagnosed per ADA criteria by fasting plasma glucose (FPG) ≥ 126 mg/dL, 2-hour 75g OGTT ≥ 200 mg/dL, A1C ≥ 6.5%, or random plasma glucose ≥ 200 mg/dL with classic hyperglycemic symptoms; in asymptomatic patients, diagnosis requires two abnormal results from the same sample or two separate test samples.

Prediabetes thresholds comprise FPG 100–125 mg/dL (impaired fasting glucose), 2-hour OGTT 140–199 mg/dL (impaired glucose tolerance), or A1C 5.7%–6.4%, identifying women at high risk for progression to overt diabetes and cardiovascular disease.

Metabolic syndrome is defined by NCEP ATP III criteria as ≥ 3 of 5 markers: waist circumference >35 inches in women, triglycerides ≥ 150 mg/dL, HDL-C <50 mg/dL in women, blood pressure ≥ 130/85 mmHg, and fasting glucose ≥ 100 mg/dL, closely clustering with polycystic ovary syndrome (PCOS).

Individualized glycemic targets in non-pregnant adult women range from A1C <7.0% for most adults, to stringent <6.5% for young newly diagnosed women without cardiovascular disease, and relaxed <8.0% for patients with advanced vascular complications, extensive comorbidities, or severe hypoglycemia history.

Metformin is the foundational first-line biguanide (contraindicated if eGFR <30 mL/min/1.73 m²; hold for iodinated contrast); GLP-1 receptor agonists and SGLT2 inhibitors provide cardiorenal protection and weight reduction, though GLP-1 RAs require discontinuation ≥ 2 months prior to planned conception and SGLT2 inhibitors increase risks of mycotic vulvovaginitis and euglycemic DKA.

Last updated: October 2026

Diagnostic Criteria for Diabetes Mellitus & Prediabetes

Type 2 diabetes mellitus (T2DM) arises from progressive beta-cell insulin secretory defects on a background of peripheral insulin resistance. In women, hormonal transitions across the reproductive lifespan—including polycystic ovary syndrome (PCOS), gestational diabetes mellitus (GDM), and menopause—powerfully modulate insulin sensitivity. Clinical practice guidelines from the American Diabetes Association (ADA) Standards of Care mandate rigorous biochemical thresholds to establish a formal diagnosis.

ADA Diagnostic Thresholds for Overt Diabetes Mellitus

A diagnosis of overt diabetes mellitus is confirmed when any one of the following criteria is met:

Fasting Plasma Glucose (FPG): ≥ 126 mg/dL (7.0 mmol/L), with fasting defined as no caloric intake for at least 8 hours.

2-Hour Oral Glucose Tolerance Test (OGTT): ≥ 200 mg/dL (11.1 mmol/L) following a 75-gram anhydrous glucose load.

Glycated Hemoglobin (A1C): ≥ 6.5% (48 mmol/mol), using an NGSP-certified, DCCT-standardized laboratory assay.

Random Plasma Glucose: ≥ 200 mg/dL (11.1 mmol/L) in a patient with classic symptoms of hyperglycemia (polyuria, polydipsia, unexplained weight loss) or in hyperglycemic crisis.

Important

In the absence of unequivocal symptomatic hyperglycemia , diagnosis requires two abnormal test results from either the same blood sample (e.g., FPG ≥ 126 mg/dL and A1C ≥ 6.5% drawn together) or two separate samples collected on different days. If results are discordant, repeat the test that exceeded the diagnostic cutoff.

Prediabetes Classification & Routine Screening

Prediabetes identifies individuals at high risk for progression to overt diabetes and cardiovascular disease:

Impaired Fasting Glucose (IFG): FPG 100 to 125 mg/dL (5.6 to 6.9 mmol/L).

Impaired Glucose Tolerance (IGT): 2-hour 75g OGTT 140 to 199 mg/dL (7.8 to 11.0 mmol/L).

Elevated Glycated Hemoglobin: A1C 5.7% to 6.4% (39 to 47 mmol/mol).

Screening for prediabetes and T2DM initiates at age 35 for all asymptomatic adults and repeats every 3 years. Screen earlier in women of any age with overweight or obesity (BMI ≥ 25 kg/m², or ≥ 23 kg/m² in Asian Americans) having ≥ 1 additional risk factor: first-degree relative with diabetes, high-risk ethnicity, GDM history, physical inactivity, hypertension (≥ 130/80 mmHg or on therapy), HDL-C <35 mg/dL, triglycerides >250 mg/dL, or PCOS.

  • Glycemic Category Fasting Plasma Glucose (FPG) 2-Hour 75g OGTT Glycated Hemoglobin (A1C)
  • Normal <100 mg/dL (5.6 mmol/L) <140 mg/dL (7.8 mmol/L) <5.7% (39 mmol/mol)
  • Prediabetes 100–125 mg/dL (5.6–6.9 mmol/L) 140–199 mg/dL (7.8–11.0 mmol/L) 5.7%–6.4% (39–47 mmol/mol)
  • Diabetes Mellitus ≥ 126 mg/dL (7.0 mmol/L) ≥ 200 mg/dL (11.1 mmol/L) ≥ 6.5% (48 mmol/mol)
  • Metabolic Syndrome in Women: NCEP ATP III Criteria & Pathophysiology

Metabolic syndrome encompasses a cluster of interrelated vascular and metabolic derangements that elevate cardiovascular mortality two-fold and T2DM risk five-fold. In women, its prevalence escalates sharply following menopause due to estrogen decline and visceral fat redistribution.

NCEP ATP III Diagnostic Criteria

Metabolic syndrome is diagnosed when a woman meets at least 3 of the following 5 criteria :

Abdominal Obesity: Waist circumference >35 inches (88 cm) in females (>40 inches / 102 cm in males; >31.5 inches / 80 cm in Asian females).

Elevated Triglycerides: Serum triglycerides ≥ 150 mg/dL (1.7 mmol/L), or on specific drug therapy.

Reduced HDL Cholesterol: Serum HDL-C <50 mg/dL (1.3 mmol/L) in females (<40 mg/dL in males), or on specific drug therapy.

Elevated Blood Pressure: Systolic BP ≥ 130 mmHg and/or diastolic BP ≥ 85 mmHg , or on antihypertensive therapy.

Elevated Fasting Glucose: Fasting plasma glucose ≥ 100 mg/dL (5.6 mmol/L), or on pharmacotherapy for elevated glucose.

Female Pathophysiology & PCOS Interplay

Visceral adipocytes hypersecrete free fatty acids into portal circulation, promoting hepatic insulin resistance and steatosis (MASLD). Concurrently, visceral fat produces inflammatory cytokines (TNF-α, IL-6) while suppressing protective adiponectin. In reproductive-age women, compensatory hyperinsulinemia stimulates ovarian theca cells to overproduce androgens and suppresses hepatic SHBG, accelerating the phenotypic triad of PCOS: hyperandrogenism, chronic anovulation, and metabolic dysfunction.

Individualized Glycemic Targets in Non-Pregnant Women

Glycemic targets balance microvascular protection against hypoglycemia hazards:

General Adult Target: A1C <7.0% (53 mmol/mol), corresponding to an estimated average glucose (eAG) of ~154 mg/dL. Preprandial capillary glucose target is 80 to 130 mg/dL (4.4 to 7.2 mmol/L); peak postprandial capillary glucose target is <180 mg/dL (10.0 mmol/L).

Stringent Target (A1C <6.5% / 48 mmol/mol): Appropriate for younger women with newly diagnosed T2DM, long life expectancy, no cardiovascular disease, and managed with low-hypoglycemia-risk agents.

Relaxed Target (A1C <8.0% / 64 mmol/mol): Indicated for patients with severe hypoglycemia history, hypoglycemia unawareness, limited life expectancy, advanced vascular complications, or extensive comorbidities.

Antihyperglycemic Pharmacotherapy

Modern antihyperglycemic selection prioritizes organ-protective agents with proven cardiorenal benefits.

Drug Class Representative Agents Mechanism of Action Cardiorenal & Weight Effects Adverse Effects & Key Clinical Warnings

Biguanides Metformin (500–2000 mg/day) Activates AMPK; decreases hepatic gluconeogenesis; improves insulin sensitivity. Weight neutral; ASCVD event reduction; inexpensive. GI intolerance (diarrhea, nausea); vitamin B12 deficiency ; contraindication: eGFR <30 mL/min/1.73 m² ; hold for iodinated radiocontrast .

GLP-1 Receptor Agonists Semaglutide , Dulaglutide , Liraglutide ; Dual GIP/GLP-1: Tirzepatide Incretin mimetics: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying. Robust weight loss; MACE reduction in ASCVD; slows DKD progression. Nausea, vomiting, diarrhea, pancreatitis; Black Box Warning: medullary thyroid cancer (MTC) / MEN2 ; discontinue ≥ 2 months before planned conception .

SGLT2 Inhibitors Empagliflozin , Dapagliflozin , Canagliflozin Inhibit SGLT2 in renal proximal tubule, promoting glucosuria (~70g/day) and natriuresis. Reduces heart failure hospitalizations (HFrEF/HFpEF); slows CKD; modest weight/BP reduction. Mycotic vulvovaginitis ; UTIs; volume depletion; euglycemic DKA ; hold 3–4 days prior to elective surgery.

Sulfonylureas Glipizide , Glimepiride Close beta-cell ATP-sensitive K+ channels, stimulating insulin exocytosis. Rapid glucose lowering; low cost. Hypoglycemia ; weight gain; glipizide preferred in renal impairment.

Insulins Basal (Glargine, Degludec); Prandial (Lispro, Aspart) Activate insulin receptors, driving cellular glucose uptake and storage. Unlimited glycemic efficacy; required for severe catabolism or A1C ≥ 10%. Hypoglycemia; weight gain; injection burden; requires capillary glucose tracking.

Clinical Administration Pearls

Metformin Safety & Contrast Protocol: Obtain baseline eGFR before starting metformin. It is contraindicated if eGFR is <30 mL/min/1.73 m²; do not initiate if eGFR is 30–44 mL/min/1.73 m² (or reduce existing dose to maximum 1000 mg/day). In patients with eGFR 30–59 mL/min/1.73 m² undergoing iodinated radiocontrast imaging, hold metformin prior to or at the time of the procedure and withhold for 48 hours afterward, restarting only after confirming stable renal function.

GLP-1 RAs & Conception: Injectable GLP-1 RAs (such as semaglutide) have prolonged half-lives and must be discontinued at least 2 months prior to planned conception to allow complete drug washout and avoid embryofetal toxicity. Transition patients to insulin or metformin preconception.

SGLT2 Inhibitors & Euglycemic DKA: Glucosuria promotes vulvovaginal candidiasis in up to 15% of women. Under physiologic stress (fasting, surgery, acute illness), glucosuria reduces insulin demand while glucagon surges, triggering lipolysis and ketogenesis with blood glucose <250 mg/dL ( euglycemic DKA ).

Tip

Screen women on long-term metformin therapy (>3–4 years) annually for vitamin B12 deficiency , particularly if presenting with paresthesias, neuropathy, or macrocytic anemia. Metformin impairs calcium-dependent ileal absorption of the B12-intrinsic factor complex.

Preventive Microvascular Surveillance & Risk Reduction

Chronic hyperglycemia silently drives microvascular damage requiring structured annual surveillance:

1. Diabetic Retinopathy

Women with T2DM must undergo a dilated eye examination by an optometrist or ophthalmologist at diagnosis and annually thereafter. Retinal capillary microaneurysms, hemorrhages, and neovascularization threaten vision. If one or more annual exams are normal, intervals may be extended to every 2 years.

2. Diabetic Nephropathy (Diabetic Kidney Disease)

Screen annually with a random spot urine albumin-to-creatinine ratio (UACR) and serum creatinine/eGFR starting at diagnosis:

Normal: UACR <30 mg/g creatinine.

Moderately Increased Albuminuria (Microalbuminuria): UACR 30 to 299 mg/g creatinine.

Severely Increased Albuminuria (Macroalbuminuria): UACR ≥ 300 mg/g creatinine.

Persistent albuminuria requires confirmation on at least 2 of 3 specimens collected over a 3- to 6-month period. First-line therapy for non-pregnant patients with confirmed UACR ≥ 30 mg/g is an ACE inhibitor or Angiotensin Receptor Blocker (ARB) titrated to maximum tolerated dose, combined with an SGLT2 inhibitor .

3. Diabetic Peripheral Neuropathy & Comprehensive Foot Exam

Perform an annual foot examination to identify loss of protective sensation (LOPS), peripheral arterial disease, and skin ulceration. LOPS testing requires the 10-gram Semmes-Weinstein monofilament applied at plantar sites, paired with at least one additional sensory test: 128-Hz tuning fork vibration at the hallux, pinprick, temperature perception, or Achilles reflex.